Interviews

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

Speakers at SLEEP 2024, the annual meeting of The American Academy of Sleep Medicine and Sleep Research Society, share their favorite parts of the conference.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses an ongoing trial and novel development in plasminogen deficiency type 1.

Allison Brager, PhD, neuroscientist, Walter Reed Army Institute of Research, discusses the interplay between physical exercise and circadian rhythms in improving cardiovascular health.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

Thomas Hall, MD, FAAD, of US Dermatology Partners, explains that disparities in dermatological care arise from the uneven distribution of dermatologists, especially in rural areas, causing delayed diagnoses and higher health care costs.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

Ravin Ratan, MD, MEd, MD Anderson, delves into how treatment paradigms and considerations differ between adult patients and pediatric patients who have soft tissue sarcomas.

Hrayr Attarian, MD, professor of neurology, Northwestern Feinberg School of Medicine, shares findings on sleep inequities that have greatly impacted refugees.

The Alliance A091902 trial is currently investigating paclitaxel with and without nivolumab in patients who are taxane naive and nivolumab plus cabozantinib in taxane-pretreated patients.

Caitlin Kindberg, patient advocate in Nashville, Tennessee, discusses her lived experience as an individual with idiopathic hypersomnia, and how the sleep disorder impacts her day-to-day life.

This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.

Christopher Depner, PhD, professor of health and kinesiology, University of Utah, shares the challenges of measuring sleep with wearable devices due to nonadherence and the need for metrics like the Sleep Regularity Index.

For June and Pride Month, we are bringing you our newest limited-edition podcast series. In this first episode, we speak with Lancaster, Pennsylvania, native and president of Lancaster Pride, Tiffany Shirley.

Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.

The BE-a-PAL study investigated potential of an algorithm-based default palliative care referral among patients who have stage III or IV lung or noncolorectal gastrointestinal cancer.

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.

The TROPiCS-02 trial studied sacituzumab govitecan vs physician’s choice of chemotherapy for HR+/HER2– breast cancer.

Ronesh Sinha, MD, attributes the rising rates of heart disease to sedentary lifestyles, stress, and health inequities, while advocating for digital health solutions to improve preventive care.

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, shares findings on the use of a novel treatment for patients with moderate to severe asthma.

In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.

Melissa B. Jones, MD, staff neuropsychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine, shares what she is looking forward to at this year's SLEEP 2024 conference.

Clinical use of liquid biopsies to determine the likelihood of CRC is the goal based on its effectiveness in recent studies.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses the clinical trials that influenced plasminogen's (Ryplazim; Kedrion Biopharma) FDA approval, as well as details valuable information for the treatment of patients with plasminogen deficiency.

Expert speakers at the American Thoracic Society (ATS) 2024 international conference share their favorite parts of the event and the key takeaways they will leave the conference with.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed how the etiologies of hepatocellular carcinoma (HCC) and underlying liver function impact treatment approach.

MicroRNAs could be a key to future testing for colorectal cancer (CRC) and determining treatment.

According to data from HHS' Office of Minority Health, Asian Americans are 60% less likely to utilize mental health services, even though 16.8% of those in the community experience mental illness.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed the most promising areas of research in Duchenne muscular dystrophy (DMD), as well as the mechanisms of gene therapies for DMD.